Advanced magnetic resonance simulator to bring new options for research and treatment

May 16, 2024

The Institute has acquired a state-of-the-art magnetic resonance simulator (MR-SIM) to be installed in 2024, made possible by generous community donations. The research applications of this technology will include new patient treatment techniques and workflows.

The MR-SIM will provide improved 3D anatomical images of tumours and surrounding tissue, as well as physiological information using advanced imaging techniques. This contributes to customized radiation treatment for cancer patients, such as optimizing the selection of the size and intensity of radiotherapy beams. The technology is a substantial upgrade to computed tomography (CT) scans. The clinical impact will be immediate by providing local and faster access to MR anatomical and advanced images, allowing this technology to benefit many more Manitoban cancer patients.

MR-SIM is still a relatively new technology for use in cancer techniques. There is a long way to go to build a full understanding of its potential application in cancer care. Therefore, wide-ranging research opportunities exist to help us take full advantage of this exciting technology. Our research will initially focus on MR-SIM workflows and processes.

This investment puts CCMB and the Institute at the forefront of MR-SIM technology in Canada. Not only does it benefit Manitoban cancer patients and cancer research, it also helps to attract top scientists and oncologists who are interested in this field. Our leadership position also generates collaborations centered around Winnipeg drawing a diverse range of national and international experts which further expands our knowledge.

Research Institute News

New book from Institute researcher, Dignity in Care: The Human Side of Medicine helps shape the future of patient care

Senior Scientist at CancerCare Manitoba Research Institute, Dr. Harvey Max Chochinov has published a new book, Dignity in Care: The Human Side of Medicine, providing insight into how the disposition and attitude of healthcare providers indelibly shape patient experience.

Read More

New trial looks at reducing bleeding risk in cancer patients while also developing novel research methods

A new Investigator-Initiated Clinical Trial (IICT) led by Primary Investigator, Dr. Brett Houston, called the MYELO-CAN TXA trial, aims to see whether Tranexamic Acid (TXA) can help prevent bleeding in patients with certain blood cancers such as acute leukemia and myelodysplastic syndrome.

Read More

$17 million lab renovation enables research creativity and innovation

A major donation from the Paul Albrechtsen Foundation facilitates the transformation of 20-year-old research laboratories into state-of-the-art facilities housing cutting-edge technology and leading scientists pursuing the next cancer breakthroughs.

Read More